![]() | Bryan R HaugenDivision of Endocrinology Metabolism and Diabetes, University of Colorado, Aurora, Colorado, USA. | Division of Endocrinology, Metabolism, and Diabetes, Department of ... |
KOL Resume for Bryan R Haugen (thyroid function, thyroid gland, system, gland, thyroid, endocrine disorders, disorders, endocrine, disorders thyroid gland)
Year | |
---|---|
2022 | Division of Endocrinology Metabolism and Diabetes, University of Colorado, Aurora, Colorado, USA. |
2021 | University of Colorado Cancer Center, Aurora, Colorado, USA. |
2020 | Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA. University of Colorado Cancer Center, Aurora, Colorado. |
2019 | University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado. |
2018 | Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, Colorado |
2017 | Department of Medicine, Division of Endocrinology, University of Colorado Cancer Center, University of Colorado School of Medicine, Denver, Colorado 80045 University of Colorado School of Medicine, Aurora, Colorado. |
2016 | Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine University of Colorado Cancer Center, University of Colorado School of Medicine Aurora Colorado |
2015 | University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, United States of America |
2014 | From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Division of Endocrinology, Diabetes, and Metabolism (R.E.S., B.R.H.), University of Colorado Denver, Aurora, Colorado 80045 |
2013 | University of Colorado School of Medicine (B.R.H.), University of Colorado Cancer Center, Aurora, Colorado 80045 |
2012 | Department of Medicine, University of Colorado School of Medicine, Aurora (B.R.H.). University of Colorado School of Medicine, 80045, Aurora, CO, USA |
2011 | University of Colorado Cancer Center, University of Colorado Denver, Aurora, CO 80045, USA |
2010 | University of Colorado Denver, School of Medicine, University of Colorado Cancer Center, Aurora, Colorado 80045 |
2009 | Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, USA Division of Endocrinology, Diabetes, and Metabolism, University of Colorado Denver, Aurora, Colorado. University of Colorado Denver (B.H.), Aurora, Colorado 80045 |
2008 | Associate Editor, Thyroid, University of Colorado at Denver, and Health Sciences Center, Aurora, CO. Division of Endocrinology, Diabetes and Metabolism (R.E.S., J.P.K., U.P., B.R.H.), University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado 80045 |
2006 | The University of Colorado Cancer Center, The University of Colorado at Denver and Health Sciences Center, Aurora, Colorado |
2005 | Division of Endocrinology, Metabolism, and Diabetes (V.S., W.R.H., W.M.W., U.P., B.R.H.), Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Aurora, Colorado 80045 Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO, USA |
2004 | Departments of Medicine, University of Colorado Health Sciences Center, Denver, CO University of Colorado Health Sciences Center, B151, 4200 E 9 Ave, Denver 80262, USA. |
2003 | Division of Endocrinology (B.R.H.), University of Colorado Health Sciences Center, Denver, Colorado 80262 Gainesville, Florida 32608-4653 |
2002 | University of Colorado Cancer Center, Denver, Colorado 80262 |
Prominent publications by Bryan R Haugen
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules ...
Known for Thyroid Nodules | Management Guidelines | Task Force | Critical Appraisal | Published Evidence |
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
[ PUBLICATION ]
PURPOSE: There are no effective therapies for patients with poorly differentiated papillary thyroid cancer (PTC) or anaplastic thyroid cancer (ATC), and metastasis to the bone represents a significantly worse prognosis. Src family kinases (SFKs) are overexpressed and activated in numerous tumor types and have emerged as a promising therapeutic target, especially in relation to metastasis. We recently showed that Src is overexpressed and activated in thyroid cancer. We therefore tested ...
Known for Thyroid Cancer | Src Kinase | Cell Cycle | Antitumor Assays | Tumor Growth |
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology
[ PUBLICATION ]
Importance: Approximately 20% of fine-needle aspirations (FNA) of thyroid nodules have indeterminate cytology, most frequently Bethesda category III or IV. Diagnostic surgeries can be avoided for these patients if the nodules are reliably diagnosed as benign without surgery.
Objective: To determine the diagnostic accuracy of a multigene classifier (GC) test (ThyroSeq v3) for cytologically indeterminate thyroid nodules.
Design, Setting, and Participants: Prospective, blinded cohort study ...
Known for Indeterminate Cytology | Thyroid Nodules | Bethesda Iii | Tumor Biopsy | Multigene Genomic Classifier |
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
[ PUBLICATION ]
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association's guidelines for the management of these disorders was published in 2006, a large amount of new information has become available, prompting a revision of the guidelines.
METHODS: Relevant articles through December 2008 were reviewed by the task force and categorized by topic and level of evidence ...
Known for Thyroid Nodules | Management Guidelines | Patients Disorders | Task Force | Suppression Therapy |
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
[ PUBLICATION ]
CONTEXT: Thyroid nodules are common in adults, but only a small fraction of them are malignant. Fine-needle aspiration (FNA) with cytological evaluation is the most reliable tool for cancer diagnosis in thyroid nodules. However, 10-40% of nodules are diagnosed as indeterminate by cytology, making it difficult to optimally manage these patients.
OBJECTIVE: The aim of this study was to establish the feasibility and role of testing for tumor-specific mutations in improving the FNA diagnosis ...
Known for Thyroid Nodules | Molecular Testing | Ret Ptc | Needle Aspiration | Fna Diagnosis |
Thyroid nodules are found in 5% to 10% of the population. While these nodules carry only a 5% to 10% risk of malignancy, tests that complement fine-needle aspiration (FNA) cytology in preoperative diagnosis and risk stratification are lacking. Telomerase is a ribonucleoprotein polymerase with activity found in many malignant tissues, but absent from most normal adult tissue. In this study, we have investigated telomerase activity in 24 thyroid tumors, 14 matched adjacent thyroid tissues, ...
Known for Telomerase Activity | Thyroid Tumors | Papillary Humans | Follicular Carcinomas | Preoperative Diagnosis |
CONTEXT: Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC).
OBJECTIVE: The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC.
DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src ...
Known for Src Fak | Therapeutic Target | Focal Adhesion | Thyroid Cancer | Kinase Complex |
Thyroid nodules are very common, and thyroid cancer is currently the fifth leading cancer diagnosis in women. The American Thyroid Association has led the development and revision of guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer (DTC). The most current revision was published in the January 2016 issue of the journal Thyroid. The current guidelines have 101 recommendations, with 8 figures and 17 tables that are hopefully helpful to those ...
Known for Thyroid Nodules | Management Patients | Current Guidelines | Fine Needle | Cancer Dtc |
CONTEXT: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal.
OBJECTIVE: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life ...
Known for Thyroid Hormone Withdrawal | Rhtsh Patients | Human Thyrotropin | Healthrelated Quality | General Population Domains |
Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis
[ PUBLICATION ]
BACKGROUND: Serum thyrotropin (TSH) concentration and thyroid autoimmunity may be of prognostic importance in differentiated thyroid cancer (DTC). Preoperative serum TSH level has been associated with higher DTC stage in cross-sectional studies; data are contradictory on the significance of thyroid autoimmunity at the time of diagnosis.
OBJECTIVE: We sought to assess whether preoperative serum TSH and perioperative antithyroglobulin antibodies (TgAb) were associated with thyroid cancer ...
Known for Differentiated Thyroid Cancer | Thyroglobulin Antibody Status | Preoperative Serum | Tsh Level | Dtc Patients |
Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue
[ PUBLICATION ]
In order to better understand basic mechanisms of tumor development and identify potential new biomarkers, we have performed difference gel electrophoresis (DIGE) and peptide mass fingerprinting on pooled protein extracts from patients with papillary thyroid carcinoma (PTC) compared with matched normal thyroid tissue. Image analysis of DIGE gels comparing PTC and matched normal thyroid tissue protein indicated that 25% of the protein spots were differentially expressed at a 2.5-fold ...
Known for Papillary Thyroid Carcinoma | Protein Expression | Normal Thyroid | Gel Electrophoresis | Spectrometry Mass |
Bryan R Haugen: Influence Statistics
Concept | World rank |
---|---|
levels rexinoid | #1 |
papillary galectin | #1 |
a375dro lgd1069 | #1 |
thyrotropederived alphatsh cells | #1 |
negative wbs evaluation | #1 |
patients negative wbs | #1 |
nuclear receptor therapies | #1 |
recombinant pit1 extracts | #1 |
gec benign cases | #1 |
proteomic analysis ptc | #1 |
lenvatinib immune | #1 |
src azd0530 | #1 |
primary dtcs | #1 |
analysis txnip | #1 |
thyroidectomy ttx | #1 |
patients indeterminate thyroid | #1 |
inhibition mkk1 2 | #1 |
thyroid specialists | #1 |
expression rxrgamma | #1 |
basis risk groups | #1 |
evaluation tg | #1 |
testing methodology improvements | #1 |
s100a2 expression rxr | #1 |
patients extracervical metastases | #1 |
mice lowdose lenvatinib | #1 |
follicular female humans | #1 |
parathyroidectomy clinicians | #1 |
dro xenograft | #1 |
lg101208 | #1 |
detecting papillary | #1 |
excessive survivin | #1 |
mkk1 2 ptc | #1 |
selective inhibition nfkappab | #1 |
node sonographic | #1 |
practice 830 | #1 |
pooled protein extracts | #1 |
gh3 extracts | #1 |
inhibited rexinoid | #1 |
sites trbeta2 | #1 |
a375dro m145 | #1 |
txnip pparγ | #1 |
lymphoma htert | #1 |
a375dro | #1 |
individual gel analyses | #1 |
model intracardiac | #1 |
tumor invasion combination | #1 |
challenges developing recommendations | #1 |
treatment m145 | #1 |
thyrotropinβ promoter activity | #1 |
levels pparγ depletion | #1 |
Open the FULL List in Excel | |
Key People For Thyroid Cancer
Bryan R Haugen:Expert Impact
Concepts for whichBryan R Haugenhas direct influence:Thyroid cancer, Thyroid nodules, Differentiated thyroid cancer, Cell lines, Thyroid carcinoma, Thyroid association, Promoter activity, Thyroid hormone withdrawal.
Bryan R Haugen:KOL impact
Concepts related to the work of other authors for whichfor which Bryan R Haugen has influence:Thyroid cancer, Lymph node, Radioactive iodine, Active surveillance, Carcinoma papillary, Braf mutation, Fine needle.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |